RhoGDI SUMOylation at Lys-138 increases its binding activity to Rho GTPase and its inhibiting cancer cell motility. - Test2 - elhamkhani - TriplyDB

RhoGDI SUMOylation at Lys-138 increases its binding activity to Rho GTPase and its inhibiting cancer cell motility.

RhoGDI SUMOylation at Lys-138 increases its binding activity to Rho GTPase and its inhibiting cancer cell motility.

http://www.wikidata.org/entity/Q35922304

about

Survivin - The inconvenient IAP Small-molecule SMAC mimetics as new cancer therapeutics Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion Detecting endogenous SUMO targets in mammalian cells and tissues.SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1.XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell Isorhapontigenin (ISO) inhibited cell transformation by inducing G0/G1 phase arrest via increasing MKP-1 mRNA Stability.Comprehensive identification of SUMO2/3 targets and their dynamics during mitosis.The Chinese herb isolate isorhapontigenin induces apoptosis in human cancer cells by down-regulating overexpression of antiapoptotic protein XIAP.High mobility group Box-1 inhibits cancer cell motility and metastasis by suppressing activation of transcription factor CREB and nWASP expression A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition.A novel post-translational modification of nucleolin, SUMOylation at Lys-294, mediates arsenite-induced cell death by regulating gadd45α mRNA stability.Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function.Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development.Immunological and Functional Characterization of RhoGDI3 and Its Molecular Targets RhoG and RhoB in Human Pancreatic Cancerous and Normal Cells.X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligase-mediated protein phosphatase 2A/c-Jun axis Rictor encounters RhoGDI2: the second pilot is taking a lead.Emerging roles of sumoylation in the regulation of actin, microtubules, intermediate filaments, and septins Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists.IAPs on the move: role of inhibitors of apoptosis proteins in cell migration.Small Rho GTPases in the control of cell shape and mobility.Hydrogen peroxide/ATR-Chk2 activation mediates p53 protein stabilization and anti-cancer activity of cheliensisin A in human cancer cells.Structural and Mechanistic Insights into the Regulation of the Fundamental Rho Regulator RhoGDIα by Lysine Acetylation.X-linked inhibitor of apoptosis protein (XIAP) lacking RING domain localizes to the nuclear and promotes cancer cell anchorage-independent growth by targeting the E2F1/Cyclin E axis.SUMOylation of RhoGDIα is required for its repression of cyclin D1 expression and anchorage-independent growth of cancer cells Regulation of Cellular Processes by SUMO: Understudied Topics.XIAP RING domain mediates miR-4295 expression and subsequently inhibiting p63α protein translation and promoting transformation of bladder epithelial cells Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis.NF-κB p65 Overexpression Promotes Bladder Cancer Cell Migration via FBW7-Mediated Degradation of RhoGDIα Protein.XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIβ mRNA stability.Shigella entry unveils a calcium/calpain-dependent mechanism for inhibiting sumoylation.Chemically facilitating the generation of diagnostic ions from SUMO(2/3) remnant isopeptides.Peptidomimetic inhibitors of APC-Asef interaction block colorectal cancer migration.A novel approach to the analysis of SUMOylation with the independent use of trypsin and elastase digestion followed by database searching utilising consecutive residue addition to lysine.The post-translational modification, SUMOylation, and cancer (Review).

P2860

Q26825700-1785B5E4-66A1-4017-843E-A3B5EBF665E3 Q26864204-2328F316-B7D3-4DDE-ACB0-4E9B16B1E3D2 Q27329571-0345FA47-420E-48C4-9E96-8BDE86C59FD0 Q27865266-8987094A-50FD-4643-8045-C88D2B526B0D Q30009429-06482B52-7657-4777-9FA8-F077E90451D6 Q30354484-0001D807-522E-452D-8750-5CC48855DA74 Q33757069-5C22E66E-75B3-45F9-A66C-4A43B9318416 Q33817223-30A6D9E4-1C5D-4458-BC20-496D0F546304 Q34294301-942B9B4D-BF46-4CAC-89D9-7722A7F3BF9E Q34365721-8D5EC448-CE20-481E-ADDE-A2A214D2FB8A Q34406424-B3CBF785-CCCA-454F-95B6-7EC29A422EE3 Q35103925-0590D004-FC3C-4080-B023-14509A6DEE7D Q35183971-8C7757A1-9BCE-4958-A5DE-386B1517F496 Q35832364-D021C498-3DB8-448A-B180-D11FE2DDC5AC Q36188915-1EF02D52-3583-4A36-B410-55F3AAE0A321 Q37012399-F55FFEFA-0011-44FA-BBC3-2010101B3EA4 Q37104803-7937582D-69AA-4E5A-A3FF-97A37B108ADB Q37308644-43C50ACE-E5A3-4E8B-9101-E220C874BBFE Q38087851-7103ED87-88B2-4793-AC70-2069FF572428 Q38134633-5F1890AC-3294-4D3D-8245-C3E9860D58DE Q38166254-5F29D3D8-7E05-4646-9C81-7EFAB0804965 Q38914905-F9D62A2F-B966-48EA-AA99-C595DD336DEE Q38915737-84C08109-B526-47B8-BA91-ED7F5F015488 Q38957077-8E39C500-3C5D-4799-BD9D-029E6A0ECFE8 Q39042922-F9D72D60-9F5A-49DC-982E-21DA264B99BC Q39136000-0895D9B6-B009-43ED-AFA4-E6CBB8A40987 Q39570699-54DB2293-E1B7-4DFC-B2F1-A270013783C3 Q39849534-920451F2-4DC5-4E7C-872D-D3CE4AAAC6DF Q41218420-00262B8B-FA9F-4E86-97EC-7363FBAFDC8C Q47282727-5AAE253D-C8DA-403E-A998-65635144AEAB Q47324931-BEDA069F-5C90-4D23-92DB-83600893993F Q47783371-2B6A3D64-05BB-40DF-A06F-7ADE5C1AD340 Q48009486-B7E4C4D6-3C6D-42DD-A088-1E7C543EE77C Q51287846-E0A3B515-A5DA-4A78-B074-B7F82DC30718 Q52730181-B7E10AC4-3DE8-449E-A02E-25245B19236E

P2860

RhoGDI SUMOylation at Lys-138 increases its binding activity to Rho GTPase and its inhibiting cancer cell motility.

http://www.wikidata.org/entity/Q35922304

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

RhoGDI SUMOylation at Lys-138 ...... hibiting cancer cell motility.

@ast

RhoGDI SUMOylation at Lys-138 ...... hibiting cancer cell motility.

@en

type

label

RhoGDI SUMOylation at Lys-138 ...... hibiting cancer cell motility.

@ast

RhoGDI SUMOylation at Lys-138 ...... hibiting cancer cell motility.

@en

prefLabel

RhoGDI SUMOylation at Lys-138 ...... hibiting cancer cell motility.

@ast

RhoGDI SUMOylation at Lys-138 ...... hibiting cancer cell motility.

@en

P1433

Q35922304-F7CF2AF2-F7B9-4891-BA7F-A89A11BF2AE2

P1476

Q35922304-3DF614BB-189C-474D-8FA8-391E284CE072

P2093

Q35922304-1152821D-79D9-490C-A642-A635A2869A5F

Q35922304-27DCA7BF-815C-4299-B358-0E1B6EA4EADE

Q35922304-42F1FD3C-EC80-4E49-B989-9AA8349E3B11

Q35922304-96B52806-87AF-4048-B523-63EFE9567F7F

P2860

Q35922304-0141311E-817F-4863-9B71-8B396289B239

Q35922304-0EE4ADB9-DBCA-4CEA-A7C3-6BAF28A5BDB1

Q35922304-1AEC5B32-A38F-433E-A255-547EA12398DE

Q35922304-1D3D7ED3-1305-44D3-B9AE-0480584181DC

Q35922304-23D77F3D-661F-463B-B696-21711FAB8202

Q35922304-263FE744-F319-4906-A6AD-A4FB217AD03F

Q35922304-321F4B07-4959-4001-96BE-6D0E6AF3C4E1

Q35922304-33E6C534-606D-41D8-A47B-07A10AEDB6BD

Q35922304-345DDF5C-1D45-455E-A55B-540C5E532499

Q35922304-3E700556-C025-4F41-9FF2-ACA6F001C7A3

P304

Q35922304-9C40DAE5-41E6-4084-A543-5D64F53D0E54

P31

Q35922304-16E7BAE4-938D-4645-8EED-49C6583B6D3E

P356

Q35922304-C536DDA3-2C34-408F-B527-434C0BBD74D7

P407

Q35922304-A1CE38A6-332A-4FD8-9FC7-F19430961D78

P433

Q35922304-8ADBCA7B-2BC3-406C-A04B-3D53459C1127

P478

Q35922304-BAA781C4-B23C-4CE2-9C7A-C2E342711473

P50

Q35922304-03BBDF41-02E1-4001-BBA6-7BCA77858B0D

Q35922304-0FDE7D33-8514-4295-9460-F5B232B97013

Q35922304-AF1B713F-D367-4DC8-B9C4-3349CA7BC2E7

P577

Q35922304-61B8EB45-198E-40B5-BC47-5BAF21CA2210

P5875

Q35922304-99033FC2-6D71-4129-B5AB-45D40C43780F

P698

Q35922304-52A36DCD-7909-4BA3-887E-DCC929CC6943

P932

Q35922304-2288995B-6A99-45F3-9FB1-DA1B578EE58D

P356

JBC.M111.337469

P1433

Journal of Biological Chemistry

P1476

RhoGDI SUMOylation at Lys-138 ...... nhibiting cancer cell motility

@en

P2093

Dongyun Zhang

http://www.w3.org/2001/XMLSchema#string

Jianxiu Yu

http://www.w3.org/2001/XMLSchema#string

Jingxia Li

http://www.w3.org/2001/XMLSchema#string

Yonghui Yu

http://www.w3.org/2001/XMLSchema#string

P2860

IAPs regulate the plasticity of cell migration by directly targeting Rac1 for degradation

PTEN regulation by Akt-EGR1-ARF-PTEN axis

RhoGDI: multiple functions in the regulation of Rho family GTPase activities

Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice

Rho GTPases in cell biology

SUMO: a history of modification

Concepts in sumoylation: a decade on

SUMO and ubiquitin in the nucleus: different functions, similar mechanisms?

X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility

Phosphorylation states of Cdc42 and RhoA regulate their interactions with Rho GDP dissociation inhibitor and their extraction from biological membranes

P304

13752-13760

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M111.337469

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

287

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221890618

http://www.w3.org/2001/XMLSchema#string

P698

22393046

http://www.w3.org/2001/XMLSchema#string

P932

3340185

http://www.w3.org/2001/XMLSchema#string